NSE · ZENITHDRUG
Zenith Drugs Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹134 Cr with net profit ₹10 Cr — a 7.17% net margin, versus 4.22% the period before.
Shareholding
As of 2026-03-31
- Promoter69.98%
- Public30.02%
1,435 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.21× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #1 of 50 by market cap · medians across 44 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,88,872 Cr | 84.65 | 22.5 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹48,208 Cr | 42.07 | 4.65 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹44,153 Cr | 38.91 | 9.77 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹30,382 Cr | 105.42 | 23.61 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹20,940 Cr | 31.47 | 6.21 | 17.88% | 29.09% |
| Shilpa Medicare Ltd. | ₹18,798 Cr | 66.1 | 7.26 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹18,785 Cr | 28.6 | 4.82 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹14,927 Cr | 28.89 | 4.92 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,666 Cr | 55.67 | 6.44 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,757 Cr | 53.47 | 7.24 | 12.36% | 18.59% |
| Zenith Drugs Limited(this company) | — | 20.8 | 1.1 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashZenith Drugs Limited is listed on the Indian markets with a market capitalization of Rs 135 Cr. The company reported revenue of Rs 135.93 Cr and an EPS of 2.3. Its debt-to-equity ratio stands at 0.63.
Positives
- +Revenue increased by 14.9% to Rs 135.93 Cr.
- +Promoter holding is high at 69.9757% as of March 31, 2026.
- +The promoter pledge percentage is 0%, indicating no shares are pledged.
Negatives
- −The Return on Equity (ROE) figure is not disclosed.
- −The profit margin figure is not disclosed.
- −Quarterly results are not disclosed for the company.
- −Institutional holding decreased from 7.492% in February 2024 to 0% in March 2026.
Financial Performance
Zenith Drugs Limited's annual revenue has shown growth over recent years. Revenue increased from Rs 73.5156 Cr in Mar 2021 to Rs 92.6662 Cr in Mar 2022, further rising to Rs 115.7582 Cr in Mar 2023, and reaching Rs 133.7419 Cr in Mar 2024. Net profit also increased from Rs 3.0665 Cr in Mar 2021 to Rs 9.5928 Cr in Mar 2024.
Profitability & Returns
The company's Return on Capital Employed (ROCE) is 12.71%. The earnings per share (EPS) was Rs 2.3. Annual EPS has increased from Rs 76.66 in Mar 2021 to Rs 5.63 in Mar 2024, noting a change in reporting basis or share structure. EBITDA has grown from Rs 6.0915 Cr in Mar 2021 to Rs 17.7343 Cr in Mar 2024.
Balance Sheet
Zenith Drugs Limited has a debt-to-equity ratio of 0.63. The book value per share is Rs 43.69.
Ownership & Pledges
As of March 31, 2026, promoters held 69.9757% of the company's shares. Public shareholding was 30.0243%. The promoter pledge percentage is 0%, indicating no shares held by promoters are pledged.
Shareholding Changes
Promoter holding has remained stable at 69.9757% since September 2023. Public shareholding was 0% in September 2023, increasing to 22.5323% by February 2024, and reaching 30.0243% by March 2026. Institutional holding (FIIs and DIIs) saw activity, for example, FII holding was 7.3987% in February 2024 and decreased to 0% by March 2026.
Data as of — price: 2026-09-12 · financials: Mar 24 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.